Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized vehicle-controlled Phase 2 trial of topical LFX453 in actinic keratosis
2014-003613-28Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2014
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of LFX453 in actinic keratosis (AK) (3 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability endpoints. Started Nov 2014; status: completed.
02
Drugs
LFX453
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2014-003613-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003613-28.